Immunogens, Compositions, and Methods for the Treatment of Dyslipidemia

This technology includes a novel vaccine for forming autoantibodies against apoC-III, a plasma enzyme that inhibits lipolysis. The vaccine can possibly be used to treat patients with high triglycerides and are at risk for pancreatitis and cardiovascular disease. This disclosure describes an ApoC3 immunogen that includes an antigenicApoC3 peptide linked to a bacteriophage virus-like-particle (VLP) immunogenic carrier.

Antibody Targeting of Cell Surface Deposited Complement Protein C3d as a Treatment for Cancer

This technology includes monoclonal antibodies (mAb) that specifically and with high affinity bind the final complement components C3dg and C3d (subsequently referred to as C3d), which can be used to kill tumor cells that carry C3d on their cell surface. We show that tumor cells of patients treated with the therapeutic anti-CD20 mAb ofatumumab carry C3d on the cell surface and can bind and be killed by addition of anti-C3 mAbs. In contrast, further addition of more ofatumumab has only minimal effects.

Intranasal or Inhaled Delivery of a Custom IgA Antibody for Protection Against COVID-19

This technology includes an IgA antibody, specifically designed to target the receptor binding domain of SARS-CoV-2, the virus causing COVID-19. Administered intranasally, this antibody has potential neutralizing activity, aiming to prevent COVID-19. IgA, an antibody class present in mucosal areas, plays a crucial role in immune defense at the initial site of viral infection. The primary application of this technology is envisioned as a therapeutic nasal spray, intended to prevent SARS-CoV-2 infection, particularly in high-risk populations.

Affinity Purified Polyclonal Antibody Against Vangl2 (Van Gogh-like) as a Research Tool Product

This technology includes an antibody that enables the identification and isolation of the protein and protein partners of Vangl2 for application by western blotting, immunoprecipitation and immunocytochemistry. Because planar cell polarity signaling disruption leads to direct or indirect pathologies including malformation of the neural tube, mental retardation, disruption of sensory functions (hearing, balance, vision), cancers (polykystic kidneys disease), or cardiac

A BL21 (ED3) Codon Plus Competent Cell-derived Bacterial Strain for Research Use

This technology includes a bacterial strain derived from BL21 (ED3) CodonPlus Competent Cells containing an expression vector for human POLR2C gene for research purposes. The bacterial strain can be used to produce the full-length human RNA polymerase II subunit, RPB3 protein, which can be in turn isolated and purified.

Cytochrome P450 CYP2J Polyclonal Antibodies and Recombinant Proteins for Immunoblotting and Metabolism Studies

This technology includes identified members of the mouse cytochromes P450 CYP2J subfamily and antibodies to them for P450 expression studies and metabolism research. Recombinant proteins of the CYP2J subfamily members have also been expressed. The CYP2J subfamily members have a wide tissue distribution and may be useful as model systems for studies of cardiovascular disease, drug metabolism, and toxicity.

Neutralizing Monoclonal Antibodies to Botulinum Neurotoxin Type A

Two chimpanzee mAbs specifically reacted with light chain of the botulinum neurotoxin A and neutralize the toxin in the mouse model. They can be used for emergency prophylaxis and treatment of either naturally acquired or terrorist associated botulism. Since the sequence of chimpanzee immune globulin is virtually identical to that of humans, the MAbs are not expected to have problems in repeated administration as equine antibodies. They can also be used for rapid diagnosis of botulinum neurotoxin A.

Controlled Expression and Assembly of Human Group-C Rotavirus-like Particles for Creation of Rotavirus Diagnostic Assays and Improved Vaccine Formulations

CDC researchers have developed methods of producing unlimited quantities of Group-C (GpC) rotavirus antigens. GpC rotaviruses are a major, worldwide cause of acute gastroenteritis in children and adults that is distinct from Group-A rotavirus. However, GpC rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GpC rotavirus disease.

Respiratory Syncytial Virus Immunogens for Vaccine and Therapeutics Development

CDC researchers have developed specific Respiratory Syncytial Virus (RSV) immunogens for use in the development of RSV-directed vaccines and therapeutics. RSV is the most common cause of serious respiratory disease in infants and young children and an important cause of disease in the elderly. To date, efforts to make a mutually safe and effective vaccine have been largely unsuccessful.

MDCK-based Reporter System for Detection of Influenza Viruses, Antiviral Drug Screening, and Analysis of Neutralizing Antibodies

CDC researchers have developed a Madin-Darby Canine Kidney (MDCK) reporter cell line that is exceptionally permissive for influenza virus replication and provides a highly specific, sensitive approach for the simultaneous detection and isolation of influenza viruses. Simplified antibody neutralization assays and high-throughput antiviral drug screening can also be easily and efficiently implemented using this reporter system.
Subscribe to Antibodies